The P-III trial evaluating datopotamab deruxtecan (6.0mg/kg, q3w) vs docetaxel (75mg/m2, q3w) in 600 patients with/out actionable genomic alterations previously treated with one prior therapy at sites in Asia, EU, North & South America. The trial is being jointly developed by Daiichi Sankyo & AstraZeneca
The results showed an improvement for dual 1EPs of PFS & the trial continues to evaluate the dual 1EPs of OS. The safety profile was consistent with prior trials with no new safety signals, all grade ILD was consistent with prior clinical trials & the results will be shared with the regulatory authorities
Datopotamab deruxtecan, a TROP2-directed ADC developed using DXd ADC technology. The therapy is being studied in novel combinations in multiple ongoing trials
Ref: Businesswire | Image: Daiichi Sankyo
Related News:- Daiichi Sankyo Presents P-I Trial (TROPION-PanTumor01) Results of Datopotamab Deruxtecan (Dato-DXd) for Metastatic Breast Cancer at SABCS 2022
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
